Enterome
Entity
Description
  • Value proposition

    Delivering the promise of immunotherapy

    We are a clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases.

    We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases:

    - OncoMimicsTM: highly effective, off-the-shelf therapeutic vaccines against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin B-cell lymphomas.

    - EndoMimicsTM: a pipeline of next generation bioactives acting like human hormones or cytokines for the treatment of immune diseases. EB1010, the lead candidate, is designed to provide improved therapeutic outcomes for patients with IBD.

    In addition, Enterome’s clinical candidate sibofimloc (also referred to as TAK-018) is advancing through a Phase 2 clinical trial in post-operative Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.


    Immuno-oncology, Auto-immunity, Inflammatory Bowel Diseases, Microbiome, Metagenomics, and Immunotherapies

  • Original language

    Delivering the promise of immunotherapy

    We are a clinical stage biopharmaceutical company developing first in class drugs based on our unique ability to de-code molecular interactions in the gut microbiome impacting human health.

    We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases:

    - OncoMimicsTM: highly effective, off-the-shelf immunotherapies against cancers. EO2401 is in Phase 2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin B-cell lymphomas.

    - EndoMimicsTM: a new generation of biologics targeting inflammatory diseases (EB1010) and metabolic diseases.

  • Enterome

    We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.

    • https://www.enterome.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Roche
Roche
Pharmaceutical, Biotechnology, Biotechnology Research
Roche
Pharmaceutical, Biotechnology, Biotechnology Research 		Other

19 Dec 2023


McKinsey & Company
McKinsey & Company
Consulting, Business Consulting and Services
McKinsey & Company
Consulting, Business Consulting and Services 		Other

24 Oct 2023


Gouvernement
Gouvernement
Gouvernement
Other

30 Sep 2023


Amazon Web Services (AWS)
Amazon Web Services (AWS)
IT services, IT Services and IT Consulting
Amazon Web Services (AWS)
IT services, IT Services and IT Consulting 		Other

31 May 2022


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking 		Other

30 Sep 2023


La French Tech
La French Tech
Media, Government Administration
La French Tech
Media, Government Administration 		Not capitalistic
Partnership
Event

30 Sep 2023


Seventure Partners
Seventure Partners
Startup accelerator & VC, Venture Capital and Private Equity Principals
Seventure Partners
Startup accelerator & VC, Venture Capital and Private Equity Principals 		Other

2 Nov 2023


France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research 		Not capitalistic
Not partnership
Event

30 Mar 2023


Genopole
Genopole
Biotechnology, Biotechnology Research
Genopole
Biotechnology, Biotechnology Research 		Not capitalistic
Not partnership
Event

16 Jun 2023


Omnes
Omnes
Startup accelerator & VC, Financial Services
Omnes
Startup accelerator & VC, Financial Services 		Capitalistic
Not partnership
Not event

18 Jun 2023


Similar entities
Last news
Show all articles
Social network dynamics